Amylyx Pharmaceuticals, Inc. Cost of Revenue
Amylyx Pharmaceuticals, Inc. (AMLX) reported Cost of Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-03-03
- Amylyx Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $0.00.
- Amylyx Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $0.00.
- Amylyx Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2024 was $5.95M, a 76.60% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2023 was $25.44M, a 750.02% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2022 was $2.99M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $8.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $8.00K derived: sum of 3 quarters · filed 2026-03-03 | $5.95M 10-K · filed 2026-03-03 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $8.00K derived: sum of 2 quarters · filed 2025-11-06 | $5.95M 10-Q · filed 2025-11-06 | $15.31M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $8.00K 10-Q · filed 2025-08-07 | $5.95M 10-Q · filed 2025-08-07 | $15.31M derived: sum of 3 quarters · filed 2025-08-07 | $20.53M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $5.95M 10-Q · filed 2025-05-08 | $15.30M derived: sum of 2 quarters · filed 2025-05-08 | $20.52M derived: sum of 3 quarters · filed 2025-05-08 | $26.10M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $9.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $14.58M derived: sum of 2 quarters · filed 2025-03-04 | $20.16M derived: sum of 3 quarters · filed 2025-03-04 | $25.44M 10-K · filed 2025-03-04 |
| 2023-09-30 | $5.22M 10-Q · filed 2024-11-07 | $10.80M derived: sum of 2 quarters · filed 2024-11-07 | $16.08M 10-Q · filed 2024-11-07 | $18.90M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $5.58M 10-Q · filed 2024-08-08 | $10.86M 10-Q · filed 2024-08-08 | $13.68M derived: sum of 3 quarters · filed 2024-08-08 | $13.86M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.28M 10-Q · filed 2024-05-09 | $8.10M derived: sum of 2 quarters · filed 2024-05-09 | $8.28M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.99M derived: sum of 2 quarters · filed 2024-02-22 | $2.99M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $172.00K 10-Q · filed 2023-11-09 | $172.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |